Artivion, Inc. (NYSE:AORT) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System cut its position in Artivion, Inc. (NYSE:AORT) by 3.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,472 shares of the company’s stock after selling 2,694 shares during the period. New York State Teachers Retirement System owned 0.18% of Artivion worth $1,349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its holdings in Artivion by 89.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,677 shares of the company’s stock valued at $29,000 after purchasing an additional 791 shares during the last quarter. SG Americas Securities LLC grew its position in Artivion by 7.8% in the fourth quarter. SG Americas Securities LLC now owns 13,393 shares of the company’s stock worth $239,000 after acquiring an additional 968 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Artivion by 6.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,628 shares of the company’s stock worth $267,000 after acquiring an additional 1,133 shares during the period. Advisor Group Holdings Inc. increased its stake in Artivion by 54.0% during the fourth quarter. Advisor Group Holdings Inc. now owns 3,859 shares of the company’s stock worth $47,000 after acquiring an additional 1,353 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Artivion by 7.3% in the fourth quarter. JPMorgan Chase & Co. now owns 25,958 shares of the company’s stock valued at $315,000 after purchasing an additional 1,773 shares during the period. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Artivion

In other Artivion news, SVP Jean F. Holloway sold 3,527 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $18.86, for a total value of $66,519.22. Following the transaction, the senior vice president now directly owns 131,858 shares in the company, valued at $2,486,841.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Artivion news, SVP Jean F. Holloway sold 3,527 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $18.86, for a total value of $66,519.22. Following the completion of the sale, the senior vice president now owns 131,858 shares in the company, valued at $2,486,841.88. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Andrew M. Green sold 1,462 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $20.00, for a total transaction of $29,240.00. Following the transaction, the vice president now owns 41,121 shares in the company, valued at $822,420. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 149,952 shares of company stock valued at $2,891,627. Corporate insiders own 8.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Stifel Nicolaus upped their target price on shares of Artivion from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price objective on shares of Artivion in a research report on Monday, April 8th.

Artivion Stock Down 1.6 %

Shares of Artivion stock opened at $19.99 on Thursday. Artivion, Inc. has a 52-week low of $12.16 and a 52-week high of $21.90. The company has a 50 day moving average of $19.81 and a 200 day moving average of $17.46. The company has a quick ratio of 3.43, a current ratio of 4.85 and a debt-to-equity ratio of 1.10. The company has a market capitalization of $823.59 million, a P/E ratio of -26.65 and a beta of 1.67.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, February 15th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.24. Artivion had a negative net margin of 8.67% and a positive return on equity of 3.02%. The firm had revenue of $93.67 million during the quarter, compared to the consensus estimate of $89.75 million. As a group, research analysts forecast that Artivion, Inc. will post 0.26 EPS for the current fiscal year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.